Perceptive Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-2,322,247
| Closed | -$158M | – | 126 |
|
|
2022
Q3 | $158M | Sell |
2,322,247
-692,807
| -23% | -$38.2M | 4.59% | 4 |
|
|
2022
Q2 | $96.3M | Sell |
3,015,054
-877,439
| -23% | -$25.7M | 3.02% | 8 |
|
|
2022
Q1 | $135M | Buy |
3,892,493
+442,578
| +13% | +$13.2M | 2.7% | 10 |
|
|
2021
Q4 | $101M | Sell |
3,449,915
-957,484
| -22% | -$29.7M | 1.56% | 19 |
|
|
2021
Q3 | $112M | Buy |
4,407,399
+254,710
| +6% | +$7.49M | 1.63% | 14 |
|
|
2021
Q2 | $145M | Sell |
4,152,689
-905,953
| -18% | -$35.4M | 1.89% | 14 |
|
|
2021
Q1 | $206M | Sell |
5,058,642
-616,069
| -11% | -$28.3M | 2.61% | 8 |
|
|
2020
Q4 | $246M | Sell |
5,674,711
-126,285
| -2% | -$6.23M | 2.64% | 8 |
|
|
2020
Q3 | $320M | Sell |
5,800,996
-41,104
| -0.7% | -$2.61M | 4.67% | 5 |
|
|
2020
Q2 | $369M | Sell |
5,842,100
-223,626
| -4% | -$15.3M | 5.98% | 2 |
|
|
2020
Q1 | $310M | Buy |
6,065,726
+200,000
| +3% | +$13.4M | 8.07% | 2 |
|
|
2019
Q4 | $466M | Sell |
5,865,726
-10,000
| -0.2% | -$593K | 9.26% | 1 |
|
|
2019
Q3 | $285M | Buy |
5,875,726
+100,000
| +2% | +$5.21M | 7.68% | 2 |
|
|
2019
Q2 | $304M | Buy |
5,775,726
+250,000
| +5% | +$14.4M | 6.97% | 2 |
|
|
2019
Q1 | $292M | Buy |
5,525,726
+100,000
| +2% | +$4.91M | 8.25% | 3 |
|
|
2018
Q4 | $223M | Buy |
5,425,726
+276,816
| +5% | +$10.4M | 8.48% | 2 |
|
|
2018
Q3 | $196M | Buy |
5,148,910
+320,000
| +7% | +$14.2M | 5.23% | 3 |
|
|
2018
Q2 | $218M | Sell |
4,828,910
-160,156
| -3% | -$7.29M | 5.72% | 3 |
|
|
2018
Q1 | $241M | Buy |
4,989,066
+100,000
| +2% | +$5.58M | 6.75% | 3 |
|
|
2017
Q4 | $192M | Buy |
4,889,066
+625,000
| +15% | +$23.3M | 6.38% | 3 |
|
|
2017
Q3 | $132M | Buy |
4,264,066
+330,139
| +8% | +$9.28M | 5.06% | 4 |
|
|
2017
Q2 | $108M | Buy |
3,933,927
+74,949
| +2% | +$2.23M | 5.41% | 4 |
|
|
2017
Q1 | $142M | Buy |
3,858,978
+730,000
| +23% | +$18.4M | 8.1% | 2 |
|
|
2016
Q4 | $45.2M | Buy |
3,128,978
+794,810
| +34% | +$14M | 3.22% | 9 |
|
|
2016
Q3 | $53.8M | Buy |
2,334,168
+126,500
| +6% | +$2.41M | 3.47% | 6 |
|
|
2016
Q2 | $36.6M | Buy |
2,207,668
+910,200
| +70% | +$18.4M | 2.54% | 8 |
|
|
2016
Q1 | $20.6M | Buy |
1,297,468
+110,838
| +9% | +$1.97M | 1.8% | 10 |
|
|
2015
Q4 | $38.4M | Buy |
1,186,630
+264,830
| +29% | +$11.5M | 2.84% | 8 |
|
|
2015
Q3 | $38.9M | Buy |
+921,800
| New | +$43.5M | 3.1% | 6 |
|
Other funds holding GBT
Perceptive Advisors's GBT Position: Q4 2022 in Review
Perceptive Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 2,322,247 shares — an estimated $158M sold.
Perceptive Advisors first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $466M in Q4 2019. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Perceptive Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Perceptive Advisors sold 2,322,247 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $158M.
- Perceptive Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Perceptive Advisors's Global Blood Therapeutics, Inc. position peaked at $466M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Perceptive Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.